AMP German Cannabis Group Inc. announced the Thuringian State Office for Consumer Protection has granted an import licence for cannabis products for medical purposes for Germany according to Section 72 of the German Medicine Law to Alternative Medical Products GmbH (“AMP Germany”), a wholly-owned subsidiary of AMP. The TLV deals with fundamental matters of economic consumer protection and consumer policy for the Free State of Thuringia in Germany.
The import license allows AMP to import medical cannabis purchased from outside the European Union into Germany. Once imported into Germany, AMP sells the European Union-Good Manufacturing Practices (EU-GMP) medical cannabis flower to pharmaceutical distributers who supply to German pharmacists. AMP’s supply chain across Germany is currently being EU-GMP audited to ensure the quality and integrity of the medical cannabis is maintained during transportation, warehousing, testing and distribution. This audit should be successfully finalized before year-end.
AMP has entered into supply agreements to purchase collectively 2,400 kg of EU-GMP medical cannabis annually from two producers once they have obtained their Health Canada sales license and received EU-GMP certification from TLV. AMP has entered into a multi-year distribution agreement for the sale of 1,200 kg annually in the first year of EU-GMP medical cannabis with a German pharmaceutical distributor. AMP anticipates entering into additional supply and pharmaceutical distribution agreements before year-end.
Dr. Stefan Feuerstein, Managing Director of AMP Germany, commented, “AMP receiving its import license according to § 72 AMG (German Medicine Law) after a stringent audit is an important step to be fully capable to import EU-GMP medical cannabis into Germany.”
Mr. Alex Blodgett, CEO of AMP, commented, “AMP has put all the pieces together for it to be one of the first significant importers of medical cannabis to Germany that is not involved in cultivation. In the near future, we plan to enter into additional supply agreements for EU-GMP medical cannabis for the growing German market from international partners.”